

INTRODUCTION

In several European countries, the incidence of primary congenital hypothyroidism (PCH) seems to increase in the last decade, especially in countries that have lowered the newborn screening TSH cutoff.

In Flanders, two centers manage since 2012 the newborn screening for PCH and these maintained the same TSH assay and cutoff (15 mU/L).

AIM

We studied in Flanders

- Current incidence of PCH
- Etiology of PCH
- Clinical characteristics of infants with PCH
- Initiation of thyroxine treatment

METHOD

Inclusion: All screened infants between 2012 and 2017

Single center (VCBMA), covering about half of the newborns in Flanders.

Collected data when diagnosed with PCH:

- Birth data,
- Results of hormonal measurements at screening and at recall
- Scintigraphy and ultrasound results at initial evaluation
- Data on thyroxine treatment initiation

INCIDENCE AND ETIOLOGY OF PRIMARY CONGENITAL HYPOTHYROIDISM IN FLANDERS

- 201 201 201
- 201
- 201
- 201 Tota

A low serum FT4 (< 15 pmol/L) was present in 36 newborns.

Abnormalities in thyroid morphogenesis are diagnosed in 69 %.

No fetal growth difference is observed between the different etiologies of PCH , but a female gender excess is present in the newborns with ectopy.

Newborns with apparent thyroid aplasia receive the highest dose. Thyroxine treatment is initiated before the age of 14 days in 87.5 % of the newborns.

<u>Ryckx Sofie</u>¹, De Mey Lynn², Marcelis Lionel³, Vanbesien Jesse¹, Gies Inge¹, Staels Willem¹, Regal Luc³, De Schepper Jean^{1,3}. ¹ Free University of Brussels – Brussels University Hospital, Department of Pediatric Endocrinology ² Free University of Brussels, Faculty of Medicine and Pharmacy ³ Flemish Center Brussels for the detection of congenital disorders

RESULTS

Table 1: Incidence of CHT

ar	Screened children	Children with CHT	Incidence of CHT
L2	28511	4	1/7128
L3	28571	5	1/5714
L4	28384	3	1/9461
L5	27535	13	1/2118
L6	27904	5	1/5581
L7	26748	10	1/2675
al	167653	40	1/4191

During the study period, 167,653 live newborns were screened for PCH, and thyroxine treatment was started in 40 (22 females [F] and 18 males [M]) newborns after confirmed PCH (serum TSH > 20 mU/L at recall).

The yearly number of treated newborns varied greatly (between 3 and 15 per year), but without a clear increase.

Based on scintigraphy (n = 29) and/or ultrasound (n = 32), a diagnosis of gland in situ, ectopy, aplasia and hypoplasia and no imaging was made in respectively 12 (5F), 15 (11 F), 10 (5 F) and 2 (0 F) and 1 (0 F) newborns.

CONCLUSIONS

The overall incidence of PCH is 1 in 4191 live newborns.




Table 2:

Number

Gestation

Birth weig

Birth leng

Birth head circumfer

No fetal growth differences were seen between the different etiologies. Thyroxine was started at a median (range) age of 10 (3-18) days (n = 35 before day 14). The thyroxine starting dose ranged between 25 (n=6) and 50 μ g (n = 10). Newborns with apparent aplasia had the lowest FT4 concentrations (median (range) 3 (0.4 -18) pmol/l) and received the highest starting dose (12.6 (7.6-20.4) µg/kg/day) when compared with the other etiologies.

REFERENCES

1. J. Leger. European Society of Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. Hormone research in Paediatrics. 2014; 81: 80-103

American Academy of Pediatrics, Susan R. Rose, American Thyroid Association, Rosalind S. Brown and Lawson Wilkins Pediatric Endocrine Society. Update of Newborn Screening and Therapy for Congenital Hypothyroidism. Pediatrics. 2006; 117;2290.

. Edgar J. Schoen, Wesley Clapp, Trinh T. To and Bruce H. Fireman. The Key Role of Newborn Thyroid Scintigraphy With Isotopic Iodide (123I) in Defining and Managing Congenital Hypothyroidism. Pediatrics, 2004, 114 (6) e683-e688

4. Il Soon Park, Jong Seo Yoon, Cheol Hwan So, Hae Sang Lee, Jin Soon Hwang. Predictors of transient congenital hypothyroidism in children with eutopic thyroid gland. J Pediatr Endocrinol Metab 2017; 22: 115-118.





Universitair Ziekenhuis Brussel

Pocher. Possion

202 ESPE

	_				
Clinical	charact	oricticc	and th	oatman	t of CHT
CIIICal	Claraci	ensuics		eaunen	ГОГСПІ

	CHT median (min-max)	Starting dose median (min-max)
of cases	4()	11.8 µg/kg/dag (7.7-31.6)
nal age (weeks)	40 (25; 42)	
ght (SDS)	0.00 (-2.31- 2.57)	
gth (SDS)	-0.14 (-1.93-2.89)	
d rence (SDS)	0.30 (-2.70-2.60)	

ACKNOWLEDGEMENTS

We wish to thank Lynn Puttemans for logistical help and the treating physicians for their collaboration

CONTACT INFORMATION

Sofie.Ryckx@zna.be

